

Understanding TERT Promoter Mutations: a Common Path to Immortality

Robert J.A. Bell¹, H. Tomas Rube², Ana Xavier-Magalhães^{1,3,4}, Bruno M. Costa^{3,4}, Andrew Mancini¹, Jun S. Song⁵, Joseph F. Costello¹

Affiliations:

¹Department of Neurological Surgery, University of California, San Francisco.

²Department of Biological Sciences, Columbia University, New York, NY, USA

³Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Campus de Gualtar 4710-057 Braga, Portugal.

⁴ICVS/3B's-PT Government Associate Laboratory, Braga/Guimarães, Campus de Gualtar 4710-057 Braga, Portugal.

⁵Department of Bioengineering and Physics, University of Illinois, Urbana-Champaign

Corresponding Author:

Joseph Costello
Box 0875, UCSF
San Francisco, CA 94143-0875
Phone: (415) 514-1183
Email: joseph.costello@ucsf.edu

Financial Support:

Support was provided from a generous gift from the Dabbieri family(RJB,AM,JFC), the Hana Jabsheh Research Initiative (RJB,AM,JFC), and NIH grants NCI P50CA097257 (RJB,AM,JFC), P01CA118816-06 (RJB,AM,JFC), R01HG003008 (HTR), and R01CA163336 (JSS). Additional support was provided from the Sontag Foundation Distinguished Scientist Award (JSS), Fundação para a Ciência e Tecnologia SFRH/BD/88220/2012 (AXM), IF/00601/2012 (BMC), Programa Operacional Regional do Norte (ON.2—O Novo Norte) (BMC), Quadro de Referência Estratégico Nacional (BMC), and Fundo Europeu de Desenvolvimento Regional (BMC).

Conflict of interest disclosure:

JFC and RJB are co-founders of Telo Therapeutics Inc.

Abstract

Telomerase (TERT) activation is fundamental step in tumorigenesis. By maintaining telomere length, telomerase relieves a main barrier on cellular lifespan, enabling limitless proliferation driven by oncogenes. The recently discovered, highly recurrent mutations in the promoter of TERT are found in over 50 cancer types, and are the most common mutation in many cancers. Transcriptional activation of TERT, via promoter mutation or other mechanisms, is the rate-limiting step in production of active telomerase. While TERT is expressed in stem cells, it is naturally silenced upon differentiation. Thus, the presence of TERT promoter mutations may shed light on whether a particular tumor arose from a stem cell or more differentiated cell type. It is becoming clear that TERT mutations occur early during cellular transformation, and activate the TERT promoter by recruiting transcription factors that do not normally regulate TERT gene expression. This review highlights the fundamental and widespread role of TERT promoter mutations in tumorigenesis, including recent progress on their mechanism of transcriptional activation. These somatic promoter mutations, along with germline variation in the TERT locus also appear to have significant value as biomarkers of patient outcome. Understanding the precise molecular mechanism of TERT activation by promoter mutation and germline variation may inspire novel cancer cell-specific targeted therapies for a large number of cancer patients.

Telomeres are composed of 'TTAGGG' repeats at the end of chromosomes, and telomere length plays a critical role in multiple human diseases including cancer (1,2). Telomere length is regulated by telomerase, the large multicomponent reverse transcriptase that recognizes, binds, and elongates the telomere ends using its intrinsic RNA template (3,4). The *TERT* gene encodes the catalytic subunit of telomerase, and its transcriptional regulation is usually the limiting step in telomerase activity(5-8). Telomerase activity is silenced in the majority of normal tissues, causing telomeres to shorten with each successive round of cell division (9,10). Eventually, a critical telomere length is reached(9,11-13), and cells enter replicative senescence(14-16). In contrast, cells that require high rates of self-renewal such as cells in the ovary(10), intestinal epithelium(17), and hematopoietic stem cells(18) have telomerase activity and can maintain telomere length over many cell divisions. The expression of telomerase is considered a hallmark of tumorigenesis, as over 90% of human cancers express the enzyme (10,19,20). The cancers found to be telomerase negative use an alternative mechanism of telomere lengthening termed ALT(21-23). Furthermore, germline variation in genes involved in telomere regulation such as *RTEL1*, *POT1*, *TERC*, *TERT*, and genes of the CST complex underlies increased risk of glioma (24-27), melanoma(28), and cancers of the lung(29,30), bladder(28), and pancreas(31).

In 2013, two hotspot point mutations were found in the *TERT* promoter in 71% of melanomas (32,33). The mutations were located 124bp and 146bp upstream of the translation start site and referred to as C228T and C250T, respectively, based on their hg19 genomic coordinates. The mutations are typically heterozygous, occur in a mutually exclusive fashion, and both create an identical 11bp sequence 'CCCGGAAGGGG'. The mutated sequence has an increased similarity to an ETS binding motif, leading to the hypothesis that the mutations generate a de-novo binding site for an activating ETS family transcription factor (TF). Soon after their initial discovery, the *TERT* promoter mutations were found to be the most common point

mutations in several tumor types including 83% of glioblastoma(34), 71% of melanoma(32,33), 66% of bladder cancer(35), and 47% of hepatocellular carcinoma(34,36). To date, the hotspot mutations have been identified in over 50 distinct cancer types (figure 1). Both mutations activate *TERT* promoter activity and *TERT* gene transcription (32,33). In bladder cancer, Borah and Xi et al. have also demonstrated that the promoter mutations are associated with increased telomerase activity and stable telomere length(37). Less commonly, *TERT* can be activated by other genetic mechanisms including rare point mutations at other promoter positions(38), rearrangements(39,40), duplication(41), or amplification(42,43). *TERT* promoter mutations were not detected in other common cancer types, such as breast and prostate cancer (figure 1 legend).

The high frequency of *TERT* promoter mutations in just two nucleotide positions strongly implicates them as driver events, arising upon tumor initiation or potentially later in tumor evolution(44). However, recent studies suggest *TERT* promoter mutations are among the earliest genetic events in bladder cancer(35), hepatocellular carcinoma(45), thyroid carcinoma(46), cutaneous melanoma(47-49), basal cell and squamous cell carcinoma(50), and oligodendroglioma(51). *TERT* promoter mutation may be the second genetic event following the activation of an oncogenic signaling pathway, such as MAP kinase signaling in melanoma (47) or Wnt signaling in hepatocellular carcinoma(45). It is unclear whether reactivation of telomerase through *TERT* promoter mutation is required only for early stages of tumorigenesis or is also necessary for sustained neoplastic growth(37).

Stem cells have been proposed as the cell of origin in multiple types of cancer. Because these cells express *TERT*, tumors originating from stem cells may not require *TERT* promoter mutations to activate telomerase and maintain telomere function. Interestingly, *TERT* promoter mutations occur most frequently in cancers with low rates of self-renewal, such as cancers of

the brain, liver, and melanocytes(34). In human embryonic stem cells genetically engineered to contain the hotspot mutations, there was little effect on *TERT* expression, but these cells failed to silence *TERT* upon differentiation(52). These observations raise the possibility that cells with low rates of self-renewal and lack of *TERT* expression acquire a *TERT* promoter mutation to avoid replicative senescence during early carcinogenesis. In contrast, transformation of *TERT*-expressing stem cells such as hematopoietic stem cells may not require promoter mutation to maintain *TERT* expression through tumorigenesis. As an alternative to mutation, *TERT* promoter activation may occur through an epigenetic switch(53). Stern et al. 2015 has additionally suggested that *TERT* promoter mutations can convert the silent *TERT* promoter into an active chromatin state(54).

Germline variation near or within the *TERT* gene is associated with telomere length in peripheral blood leukocytes and risk of *TERT* promoter mutant (25,55) and non-mutant (56-58) cancer. Notably, the *TERT* promoter polymorphism rs2853669 modulates the prognostic value of *TERT* promoter mutations across a variety of tumor types. The rs2853669 common allele is thought to create a binding site for the ETS/TCF factor Ets2 99bp and 121bp upstream of the C250T and C228T hotspot mutations, respectively(59). In the presence of a somatic *TERT* promoter mutation in the tumor, patients with the rs2853669 common allele showed decreased overall survival and increased tumor recurrence rate in bladder cancer(59,60) and decreased mean survival in glioma (61). Additionally, gliomas bearing the common allele of rs2853669 and a hotspot promoter mutation have significantly increased *TERT* expression compared to tumors with the rs2853669 minor allele, suggesting a possible molecular link between the hotspot mutation sites and the rs2853669 site in the *TERT* promoter(62). However, other studies reported the minor allele to associate with decreased overall survival in *TERT* mutant glioma(63) or have no prognostic effect with either allele(64). Thus, determining the precise

prognostic value of rs2853669 may require larger sample sizes and cohorts with more extensive treatment information.

The prognostic power of *TERT* promoter mutations highlights their potential use as clinical biomarkers. In addition to bladder cancer and glioma, the presence of *TERT* promoter mutations is associated with decreased overall survival in medulloblastoma(65), thyroid cancer(66-68), urogenital cancer(59,69), melanoma(70,71), and laryngeal tumors(72). Furthermore, *TERT* promoter mutations may serve as biomarkers to distinguish subtypes of urological malignancies(35,73-75). They also predict malignant transformation of premalignant nodules in HCC(76) and meningiomas(77), and associate with the anatomical origin of squamous cell carcinomas(78). A new and powerful molecular classification of glioma subtypes is based on three common genetic alterations in the tumors, including *TERT* promoter mutations(79-81), that predicts overall survival with higher accuracy than traditional classification based on histology. The molecular classification will be useful in clinical trials to enable improved interpretation of patient response to therapy (81,82).

Based on the identical 11bp DNA sequence motif created by the *TERT* promoter mutations, the mechanism of promoter activation was hypothesized to involve recruitment of an ETS family transcription factor. Indeed, site-directed mutagenesis of the hotspot positions in a promoter-reporter plasmid revealed the generated ETS motif was necessary for promoter activation(41). There are 27 ETS factors however, and most bind a very similar DNA sequence in vitro, suggesting extensive redundancy(83). It was therefore surprising that GABPA but not other ETS factors was identified to be the transcription factor responsible for mutant *TERT* activation(41). GABPA is the only ETS factor of those expressed in glioblastoma (GBM) to selectively regulate the mutant *TERT* promoter without affecting wild-type promoter activity. Single molecule binding assays, chromatin immunoprecipitation and sequencing (ChIP-seq) and

ChIP-qPCR analysis revealed that GABPA is exclusively recruited to the mutant allele *in vitro* and *in vivo*. GABPA binding to the mutant *TERT* promoter was conserved across cell lines from multiple cancer types including GBM, melanoma, hepatocellular carcinoma, and neuroblastoma. This finding was later corroborated in bladder cancer(54). While the other ETS factors are active as a monomer GABPA is unique in that it can only function as a heterodimer or heterotetramer with GABPB(84-86). Analysis of the sequence content of GABPA binding sites at the *TERT* promoter and genome wide from GABPA ChIP-seq data, suggested that the promoter mutations create the second in a pair of binding motifs that are optimally spaced to recruit the heterotetramer complex. This work begins to explain how the mutant *TERT* promoter is activated, though factors binding to the sequences up and downstream of the mutation sites may cooperate (figure 3). This study also provided supporting evidence as to why GABPA is a key, mutation-selective activating factor across multiple cancer types. It also raised a new, testable hypothesis as to why the mutations occur in the same two nucleotides in nearly all *TERT*-mutant tumors

Li et al. have suggested that the C228T and C250T mutations may be subject to differential regulatory mechanisms in glioma(87). Utilizing a cell culture system of non-canonical NF-kB activation, p52 is recruited to the C250T mutation but not to C228T. Furthermore, p52 cooperated with ETS1/2 to induce *TERT* expression specifically in the context of C250T. That C228T and C250T are not functionally identical is independently supported by the fact that the two mutations do not occur at equal frequency within a given tumor type. For example, in one study of glioma, while 48% of patients were found to harbor the C228T mutation, only 22% contained the C250T mutation(51) (figure 2). Whether these biases in mutation prevalence reflect differences in upstream regulatory factors or significant differential effects on downstream *TERT* expression remains to be determined.

The mechanism of mutant *TERT* promoter activation has just begun to be revealed. It will be critical to elucidate the similarities and differences of all the proteins bound to the mutant promoter compared to the active wild-type *TERT* promoter. For example, Myc(88), Sp1(89), USF1/2(90), Id2(91), and Ets2(92) have all been reported to regulate *TERT* promoter activity. Analysis of ENCODE ChIP-seq in HepG2 and SK-N-SH cells shows binding of the MAX transcription factor downstream of GABPA in the *TERT* promoter. However, this is also observed in the MCF7 breast cancer cell line that is wild-type at the *TERT* promoter, implying that MAX could be involved in regulation from the mutant and wild-type *TERT* promoter (figure 3).

It remains unclear how GABPA is regulated by upstream signaling pathways within the context of *TERT* promoter mutant cancer cells. GABPA function is primarily regulated by its transport to the nucleus. Both the MAPK and Hippo signaling pathways modulate GABPA activity through post-translational modification and nuclear localization in different cell contexts (93,94). *EGFR* amplification and *BRAF*^{V600E} mutation, both MAPK activating events, significantly co-occur with *TERT* promoter mutations in GBM and melanoma, respectively (32,34).

An increased mechanistic understanding of both germline variation and somatic mutation at the *TERT* promoter could help inform newer strategies to therapeutically target telomerase. Several attempts have been made to block telomerase activity in cancer patients, but thus far none are standard of care. Past strategies have included the use of small molecules, immunotherapy, gene therapy and G-quadruplex stabilizers(95). One promising approach is the antisense oligonucleotide therapy GRN163L from Geron. By hybridizing and inhibiting the RNA template of telomerase, GRN163L reduced tumor growth in preclinical models of breast cancer (96,97), GBM(98,99), and pancreatic(100) and liver cancer(101). The preclinical success has not translated to clinical benefit in cancer patients, as trials in breast,

lung, and pediatric CNS cancers were discontinued(102-104). In each trial, frequent grade III/IV hematopoietic toxicities were observed, potentially resulting from telomerase inhibition in healthy hematopoietic stem cells. As a result, trials with GRN163L have been restricted to myeloproliferative diseases. Promising results have been reported in Myelofibrosis patients treated with GRN163L(105). Determining whether *TERT* promoter mutations can act as a biomarker to predict patient response to existing telomerase inhibitor trials, or foster the creation of new telomerase inhibitors will be an exciting area of research in the future.

Grant Support

Support was provided from a generous gift from the Dabbieri family(RJB,AM,JFC), the Hana Jabsheh Research Initiative (RJB,AM,JFC), and NIH grants NCI P50CA097257 (RJB,AM,JFC), P01CA118816-06 (RJB,AM,JFC), R01HG003008 (HTR), and R01CA163336 (JSS). Additional support was provided from the Sontag Foundation Distinguished Scientist Award (JSS), Fundação para a Ciência e Tecnologia SFRH/BD/88220/2012 (AXM), IF/00601/2012 (BMC), Programa Operacional Regional do Norte (ON.2—O Novo Norte) (BMC), Quadro de Referência Estratégico Nacional (BMC), and Fundo Europeu de Desenvolvimento Regional (BMC).

Figures

Figure 1: Prevalence of *TERT* promoter mutations in human cancers.

The frequency of *TERT* promoter mutations is plotted for all tumor types in which at least 20 samples have been tested. Horizontal lines indicate Wilson score confidence intervals. In contrast to these tumor types, no *TERT* promoter mutations were found in the following cancers: oral mucosal melanoma (n=39 (106)), pilocytic astrocytoma (n=111 (107)), medullary thyroid carcinoma (n=24 (34), n=28 (44), n=37 (67)), metastatic bladder adenocarcinoma (n=30 (108)), colorectal adenocarcinoma (n=22 (34)), gastric cancer (n=74 (109)), breast carcinoma (n=88 (34)), cholangiosarcoma (n=28, (34)), dedifferentiated liposarcoma (n=61 (110)), leiomyosarcoma (n=27 (110)), undifferentiated pleomorphic sarcoma (n=40 (110)), myeloid leukemia (n=48 (34)), pancreatic cancer (n=46 (109)), pancreatic acinar carcinoma (n=25 (34)), pancreatic ductal adenocarcinoma (n=24 (34)), prostate carcinoma (n=34 (34)), endometrioid carcinoma (n=43 (111)), leiomyosarcoma (n=22 (111)), endocervical adenocarcinoma (n=25 (111)), endometrial cancer (n=24 (111)), intrahepatic cholangiocarcinoma (n=52 (37)), thymoma (n=47 (109)), head and neck paraganglioma (n=37 (112)), lung squamous cell carcinoma (n=25 (78)).

Figure 2: Percentage of C228T mutations within tumor types harboring high *TERT* promoter mutation frequency.

Each oval indicates the percentage of C228T mutations observed within *TERT* mutant tumors (aggregated across studies) for a specific cancer type. A value of 50% means there is equal occurrence of C228T and C250T within that cancer type. Only studies with 20 or more samples and only cancer types with 20 or more observed mutations were included. The cancer types were grouped as in figure 1.

Figure 3: GABPA and MAX binding at the *TERT* promoter in ENCODE cell lines.

ChIP-seq coverage for GABPA and MAX is displayed at the *TERT* promoter for MCF-7 (WT), HepG2 (C228T), and SK-N-SH (C228T) cells respectively. MAX binding is observed in all three cell lines while GABPA binding is specifically associated with *TERT* promoter mutation status.

Figure 4: A model for the activation of the mutant *TERT* promoter by GABP recruitment as a heterotetramer.

The GABP heterotetramer is made up of two GABPA(green) and two GABPB(blue) subunits. GABPA is responsible for direct DNA binding, and one subunit is hypothesized to bind to the promoter mutation (stars in blue sections) while the other binds to a native ETS binding site further downstream (red highlighted section).

Bibliography

1. Moyzis RK, Buckingham JM, Cram LS, Dani M, Deaven LL, Jones MD, et al. A highly conserved repetitive DNA sequence, (TTAGGG)_n, present at the telomeres of human chromosomes. 1988 Sep 1;85(18):6622–6626.
2. Blasco MA. Telomeres and human disease: ageing, cancer and beyond. *Nat Rev Genet.* 2005 Aug 1;6(8):611–22.
3. Bryan TM, Cech TR. Telomerase and the maintenance of chromosome ends. *Curr Opin Cell Biol.* 1999 Jun 1;11(3):318–24.
4. Greider CW, Blackburn EH. Identification of a specific telomere terminal transferase activity in tetrahymena extracts. *Cell.* 1985 Jan 1;43(2):405–13.
5. Weinrich SLS, Pruzan RR, Ma LL, Ouellette MM, Tesmer VMV, Holt SES, et al. Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTERT. *Nat Genet.* 1997 Dec 1;17(4):498–502.
6. Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, Lingner J, et al. Telomerase catalytic subunit homologs from fission yeast and human. *Science [Internet].* 1997 Aug 15;277(5328):955–9.
7. Meyerson M, Counter CM, Eaton EN, Ellisen LW, Steiner P, Caddle SD, et al. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. *Cell.* 1997 Aug 22;90(4):785–95.
8. Kilian A, Bowtell DD, Abud HE, Hime GR, Venter DJ, Keese PK, et al. Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex splicing patterns in different cell types. *Hum Mol Genet.* 1997 Nov 1;6(12):2011–9.
9. Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strains. *Exp Cell Res.* 1961 Jan 1;25(3):585–621.
10. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PLC, et al. Specific Association of Human Telomerase Activity with Immortal Cells and Cancer. *Science.* 1994 Dec;266(5):2011–5.
11. Shay JW, Wright WE. Hayflick, his limit, and cellular ageing. *Nat. Rev. Mol. Cell Biol.* *Nat. Rev. Mol. Cell Biol.*; 2000. pages 72–6.
12. Cong Y-S, Wright WE, Shay JW. Human telomerase and its regulation. *Microbiol Mol Biol Rev.* 2002 Sep;66(3):407–25.
13. Nandakumar J, Cech TR. Finding the end: recruitment of telomerase to telomeres. *Nat Rev Mol Cell Biol.* Nature Publishing Group; 2013 Jan 9;14(2):69–82.
14. Huschtscha LI, Holliday R. Limited and unlimited growth of SV40-transformed cells from human diploid MRC-5 fibroblasts. *J Cell Sci.* 1983 Sep 1;63:77–99.

15. Wright WE, Pereira-Smith OM, Shay JW. Reversible cellular senescence: implications for immortalization of normal human diploid fibroblasts. *Mol Cell Bio*. 1989 Jul 1;9(7):3088–92.
16. Counter CM, Avilion AA, LeFeuvre CE, Stewart NG, Greider CW, Harley CB, et al. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. *EMBO J*. 1992 May;11(5):1921–9.
17. Hiyama E, Tatsumoto N, Kodama T, Hiyama K, Shay J, Yokoyama T. Telomerase activity in human intestine. *Int J Oncol*. 1996 Sep;9(3):453–8.
18. Yui J, Chiu CP, Lansdorp PM. Telomerase activity in candidate stem cells from fetal liver and adult bone marrow. *Blood*. 1998 May 1;91(9):3255–62.
19. Phd PC-B, Phd SC, Bsc SM, Phd DG, Msc CZ, Msc TL, et al. Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study. *Lancet Oncology*. 2013 Apr 25;14(6):534–42.
20. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. *Eur. J. Cancer*. 1997 Apr;33(5):787–91.
21. Murnane JP, Sabatier L, Marder BA, Morgan WF. Telomere dynamics in an immortal human cell line. *EMBO J*. 1994 Oct 17;13(20):4953–62.
22. Bryan TM, Englezou A, Gupta J, Bacchetti S, Reddel RR. Telomere elongation in immortal human cells without detectable telomerase activity. *EMBO J*. 1995 Sep 1;14(17):4240–8.
23. Bryan TM, Englezou A, Dalla-Pozza L, Dunham MA, Reddel RR. Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. *Nat Med*. 1997 Nov;3(11):1271–4.
24. Walsh KM, Wiencke JK, Lachance DH, Wiemels JL, Molinaro AM, Eckel-Passow JE, et al. Telomere maintenance and the etiology of adult glioma. *Neuro-Oncology [Internet]*. 2015 Oct 9;17(11):1445–52.
25. Walsh KM, Codd V, Smirnov IV, Rice T, Decker PA, Hansen HM, et al. Variants near TERT and TERC influencing telomere length are associated with high-grade glioma risk. *Nat Genet*. 2014 Jul 1;46(7):731–5.
26. Wrensch M, Jenkins RB, Chang JS, Yeh R-F, Xiao Y, Decker PA, et al. Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. *Nature Publishing Group*. 2009 Jul 5;41(8):905–8.
27. Walsh KM, Codd V, Rice T, Nelson CP, Smirnov IV, McCoy LS, et al. Longer genotypically-estimated leukocyte telomere length is associated with increased adult glioma risk. *Oncotarget*. 2015 Dec 4.
28. Rafnar T, Sulem P, Stacey SN, Geller F, Gudmundsson J, Sigurdsson A, et al. Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. *Nat Genet*. 2009 Jan 18;41(2):221–7.

29. McKay JD, Hung RJ, Gaborieau V, Boffetta P, Chabrier A, Byrnes G, et al. Lung cancer susceptibility locus at 5p15.33. *Nat Genet.* 2008 Nov 2;40(12):1404–6.
30. Wang Y, Broderick P, Webb E, Wu X, Vijayakrishnan J, Matakidou A, et al. Common 5p15.33 and 6p21.33 variants influence lung cancer risk. *Nat Genet.* 2008 Nov 2;40(12):1407–9.
31. Petersen GM, Amundadottir L, Fuchs CS, Kraft P, Stolzenberg-Solomon RZ, Jacobs KB, et al. A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. *Nat Genet.* 2010 Mar;42(3):224–8.
32. Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, et al. TERT Promoter Mutations in Familial and Sporadic Melanoma. *Science.* 2013 Jan 24.
33. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA. Highly Recurrent TERT Promoter Mutations in Human Melanoma. *Science.* 2013 Jan 24.
34. Killela PJ, Reitman ZJ, Jiao Y, Bettgowda C, Agrawal N, Diaz LA, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. *Proceedings of the National Academy of Sciences.* 2013 Apr 9;110(15):6021–6.
35. Papadopoulos N, Kinde I, Munari E, Faraj SF, Hruban RH, Schoenberg MP, et al. TERT Promoter Mutations Occur Early in Urothelial Neoplasia and are Biomarkers of Early Disease and Disease Recurrence in Urine. *Cancer Res.* 2013 Oct 11;73(18):5411–8.
36. Quaas A, Oldopp T, Tharun L, Klingensfeld C, Krech T, Sauter G, et al. Frequency of TERT promoter mutations in primary tumors of the liver. *Virchows Arch.* 2014 Sep 30.
37. Borah S, Xi L, Zaug AJ, Powell NM, Dancik GM, Cohen SB, et al. Cancer. TERT promoter mutations and telomerase reactivation in urothelial cancer. *Science.* 2015 Feb 27;347(6225):1006–10.
38. Borah S, Xi L, Zaug AJ, Powell NM, Dancik GM, Cohen SB, et al. Cancer. TERT promoter mutations and telomerase reactivation in urothelial cancer. *Science.* 2015 Feb 27;347(6225):1006–10.
39. Valentijn LJ, Koster J, Zwijnenburg DA, Hasselt NE, van Sluis P, Volckmann R, et al. TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors. *Nat Genet.* Nature Publishing Group; 2015 Nov 2;47(12):1411–4.
40. Peifer M, Hertwig F, Roels F, Dreidax D, Gartlgruber M, Menon R, et al. Telomerase activation by genomic rearrangements in high-risk neuroblastoma. *Nature.* 2015 Oct 14;526(7575):700–4.
41. Bell RJA, Rube HT, Kreig A, Mancini A, Fouse SD, Nagarajan RP, et al. Cancer. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer. *Science.* 2015 May 29;348(6238):1036–9.
42. Zhu C-Q, Cutz J-C, Liu N, Lau D, Shepherd FA, Squire JA, et al. Amplification of telomerase (hTERT) gene is a poor prognostic marker in non-small-cell lung cancer. *Br*

- J Cancer. 2006 Apr 25;94(10):1452–9.
43. Kang JU, Koo SH, Kwon KC, Park JW, Kim JM. Gain at chromosomal region 5p15.33, containing TERT, is the most frequent genetic event in early stages of non-small cell lung cancer. *Cancer Genetics and Cytogenetics*. 2008 Apr;182(1):1–11.
 44. Vinagre J, Almeida A, Pópulo H, Batista R, Lyra J, Pinto V, et al. Frequency of TERT promoter mutations in human cancers. *Nature Communications*. 2013 Jan 1;4:2185–5.
 45. Nault JC, Mallet M, Pilati C, Calderaro J, Bioulac-Sage P, Laurent C, et al. High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. *Nature Communications*. 2013;4:2218.
 46. Wang N, Liu T, Sofiadis A, Juhlin CC, Zedenius J, Höög A, et al. TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA. *Cancer*. 2014 Oct 1;120(19):2965–79.
 47. Heidenreich B, Nagore E, Rachakonda PS, Garcia-Casado Z, Requena C, Traves V, et al. Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma. *Nature Communications*. 2014;5:3401.
 48. Hosler GA, Davoli T, Mender I, Litzner B, Choi J, Kapur P, et al. A primary melanoma and its asynchronous metastasis highlight the role of BRAF, CDKN2A, and TERT. *J. Cutan. Pathol*. 2015 Feb 1;42(2):108–17.
 49. Shain AH, Yeh I, Kovalyshyn I, Sriharan A, Talevich E, Gagnon A, et al. The Genetic Evolution of Melanoma from Precursor Lesions. *N Engl J Med*. 2015 Nov 12;373(20):1926–36.
 50. Scott GA, Laughlin TS, Rothberg PG. Mutations of the TERT promoter are common in basal cell carcinoma and squamous cell carcinoma. *Mod. Pathol*. 2014 Apr;27(4):516–23.
 51. Arita H, Narita Y, Fukushima S, Tateishi K, Matsushita Y, Yoshida A, et al. Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss. *Acta Neuropathol*. 2013 Aug 1;126(2):267–76.
 52. Chiba K, Johnson JZ, Vogan JM, Wagner T, Boyle JM. Cancer-associated TERT promoter mutations abrogate telomerase silencing. *Elife*. 2015 Jul 20;:1–20.
 53. Azouz A, Wu Y-L, Hillion J, Tarkanyi I, Karniguian A, Aradi J, et al. Epigenetic plasticity of hTERT gene promoter determines retinoid capacity to repress telomerase in maturation-resistant acute promyelocytic leukemia cells. *Leukemia*. Nature Publishing Group; 2010 Jan 14;24(3):613–22.
 54. Stern JL, Theodorescu D, Vogelstein B, Papadopoulos N, Cech TR. Mutation of the TERT promoter, switch to active chromatin, and monoallelic TERT expression in multiple cancers. *Genome Res*. 2015 Oct 29.

55. Mosrati MA, Malmström A, Lysiak M, Kryzstofiak A, Hallbeck M, Milos P, et al. TERT promoter mutations and polymorphisms as prognostic factors in primary glioblastoma. *Oncotarget*. 2015 Jun 30;6(18):16663–73.
56. Beesley J, Pickett HA, Johnatty SE, Dunning AM, Chen X, Li J, et al. Functional polymorphisms in the TERT promoter are associated with risk of serous epithelial ovarian and breast cancers. *PLoS ONE*. 2011 Jan 1;6(9):e24987–7.
57. Bojesen SE, Pooley KA, Johnatty SE, Beesley J, Michailidou K, Tyrer JP, et al. Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. *Nat Genet*. 2013 Apr 1;45(4):371–2.
58. Yoo SS, Do SK, Choi JE, Lee SY, Lee J, Cha SI, et al. TERT Polymorphism rs2853669 Influences on Lung Cancer Risk in the Korean Population. *Journal of Korean Medical Science*. 2015 Oct 1;30(10):1423–8.
59. Rachakonda PS, Hosen I, de Verdier PJ, Fallah M, Heidenreich B, Ryk C, et al. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism. *PNAS*. 2013 Oct 22;110(43):17426–31.
60. Hosen I, Rachakonda PS, Heidenreich B, de Verdier PJ, Ryk C, Steineck G, et al. Mutations in TERT promoter and FGFR3 and telomere length in bladder cancer. *Int J Cancer*. 2015 Oct 1;137(7):1621–9.
61. Spiegl-Kreinecker S, Lotsch D, Ghanim B, Pirker C, Mohr T, Laaber M, et al. Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis. *Neuro-Oncology*. 2015 Feb 13.
62. Labussière M, Di Stefano AL, Gleize V, Boisselier B, Giry M, Mangesius S, et al. TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations. *Br J Cancer*. 2014 Nov 11;111(10):2024–32.
63. Mosrati MA, Malmström A, Lysiak M, Kryzstofiak A, Hallbeck M, Milos P, et al. TERT promoter mutations and polymorphisms as prognostic factors in primary glioblastoma. *Oncotarget*. 2015 Jun 30;6(18):16663–73.
64. Nenchu U, Rahimian A, Giry M, Sechi A, Mokhtari K, Polivka M, et al. TERT promoter mutations and rs2853669 polymorphism: prognostic impact and interactions with common alterations in glioblastomas. *Journal of Neuro-Oncology*. Springer US; 2015 Nov 24;:1–6.
65. Remke M, Ramaswamy V, Peacock J, Shih DJH, Koelsche C, Northcott PA, et al. TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. *Acta Neuropathol*. 2013 Dec 31;126(6):917–29.
66. Melo M, da Rocha AG, Vinagre J, Batista R, Peixoto J, Tavares C, et al. TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. *The Journal of Clinical Endocrinology & Metabolism*. 2014 May;99(5):E754–65.

67. Liu T, Wang N, Cao J, Sofiadis A, Dinets A, Zedenius J, et al. The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas. *Oncogene*. 2014 Oct 16;33(42):4978–84.
68. George JR, Henderson YC, Williams MD, Roberts DB, Hei H, Lai SY, et al. Association of TERT Promoter Mutation, but Not BRAF Mutation, with Increased Mortality in PTC. *The Journal of Clinical Endocrinology & Metabolism*. 2015 Oct 13;:jc.2015–690.
69. Wu S, Huang P, Li C, Huang Y, Li X, Wang Y, et al. Telomerase reverse transcriptase gene promoter mutations help discern the origin of urogenital tumors: a genomic and molecular study. *Eur. Urol*. 2014 Feb;65(2):274–7.
70. Griewank KG, Murali R, Puig-Butille JA, Schilling B, Livingstone E, Potrony M, et al. TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma. *J Natl Cancer Inst*. 2014 Sep 1;106(9):–.
71. Pópulo H, Boaventura P, Vinagre J, Batista R, Mendes A, Caldas R, et al. TERT promoter mutations in skin cancer: the effects of sun exposure and X-irradiation. *J Invest Dermatol*. 2014 Aug 1;134(8):2251–7.
72. Qu Y, Dang S, Wu K, Shao Y, Yang Q, Ji M, et al. TERT promoter mutations predict worse survival in laryngeal cancer patients. *Int J Cancer*. 2014 Aug 15;135(4):1008–10.
73. Wang K, Liu T, Liu C, Meng Y, Yuan X, Liu L, et al. TERT promoter mutations and TERT mRNA but not FGFR3 mutations are urinary biomarkers in Han Chinese patients with urothelial bladder cancer. *Oncologist*. 2015 Mar 1;20(3):263–9.
74. Wang K, Liu T, Ge N, Liu L, Yuan X, Liu J, et al. TERT promoter mutations are associated with distant metastases in upper tract urothelial carcinomas and serve as urinary biomarkers detected by a sensitive castPCR. *Oncotarget*. 2014 Dec 15;5(23):12428–39.
75. Hurst CD, Platt FM, Knowles MA. Comprehensive Mutation Analysis of the TERT Promoter in Bladder Cancer and Detection of Mutations in Voided Urine. *Eur. Urol*. 2014 Feb 1;65(2):367–9.
76. Nault JC, Calderaro J, Di Tommaso L, Balabaud C, Zafrani ES, Bioulac-Sage P, et al. Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis. *Hepatology*. 2014 Dec;60(6):1983–92.
77. Goutagny S, Nault JC, Mallet M, Henin D, Rossi JZ, Kalamarides M. High incidence of activating TERT promoter mutations in meningiomas undergoing malignant progression. *Brain Pathol*. 2014 Mar;24(2):184–9.
78. Cheng KA, Kurtis B, Babayeva S, Zhuge J, Tantchou I, Cai D, et al. Heterogeneity of TERT promoter mutations status in squamous cell carcinomas of different anatomical sites. *Ann Diagn Pathol*. 2015 Jun 1;19(3):146–8.
79. Killela PJ, Pirozzi CJ, Healy P, Reitman ZJ, Lipp E, Rasheed BA, et al. Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult

- malignant gliomas. *Oncotarget*. 2014 Mar 30;5(6):1515–25.
80. Labussière M, Boisselier B, Mokhtari K, Di Stefano A-L, Rahimian A, Rossetto M, et al. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes. *Neurology*. 2014 Sep 23;83(13):1200–6.
 81. Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, et al. Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. *N Engl J Med*. 2015 Jun 25;372(26):2499–508.
 82. The Cancer Genome Atlas Research Network. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. *N Engl J Med*. 2015 Jun 25;372(26):2481–98.
 83. Wei G-H, Badis G, Berger MF, Kivioja T, Palin K, Enge M, et al. Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo. *The EMBO Journal*. 2010 Jun 1;29(13):2147–60.
 84. Thompson CC, Brown TA, Mcknight SL. Convergence of Ets- and notch-related structural motifs in a heteromeric DNA binding complex. *Science*. 1991 Aug 16;253(5021):762–8.
 85. Oikawa T, Yamada T. Molecular biology of the Ets family of transcription factors. *Gene*. 2003 Jan 1;303:11–34.
 86. LaMarco K, Thompson CC, Byers BP, Walton EM, Mcknight SL. Identification of Ets- and notch-related subunits in GA binding protein. *Science*. 1991 Aug 16;253(5021):789–92.
 87. Li Y, Zhou Q-L, Sun W, Chandrasekharan P, Cheng HS, Ying Z, et al. Non-canonical NF- κ B signalling and ETS1/2 cooperatively drive C250T mutant TERT promoter activation. *Nat Cell Biol*. 2015 Sep 21;17(10):1327–38.
 88. Wu KJ, Grandori C, Amacker M, Simon-Vermot N, Polack A, Lingner J, et al. Direct activation of TERT transcription by c-MYC. *Nat Genet*. 1999 Feb;21(2):220–4.
 89. Kyo S, Takakura M, Taira T, Kanaya T, Itoh H, Yutsudo M, et al. Sp1 cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT). *Nucleic Acids Res*. 2000 Feb 1;28(3):669–77.
 90. Goueli BS, Janknecht R. Regulation of telomerase reverse transcriptase gene activity by upstream stimulatory factor. *Oncogene*. 2003 Sep 11;22(39):8042–7.
 91. Xiao X, Athanasiou M, Sidorov IA, Horikawa I, Cremona G, Blair D, et al. Role of Ets/Id proteins for telomerase regulation in human cancer cells. *Exp Mol Pathol*. 2003 Dec 1;75(3):238–47.
 92. Xu D, Dwyer J, Li H, Duan W, Liu J-P. Ets2 maintains hTERT gene expression and breast cancer cell proliferation by interacting with c-Myc. *J Biol Chem*. 2008 Aug 29;283(35):23567–80.

93. Wu H, Xiao Y, Zhang S, Ji S, Wei L, Fan F, et al. The Ets Transcription Factor GABP Is a Component of the Hippo Pathway Essential for Growth and Antioxidant Defense. *CellReports*. 2013 May 30;3(5):1663–77.
94. Flory E, Hoffmeyer A, Smola U, Rapp UR, Bruder JT. Raf-1 kinase targets GA-binding protein in transcriptional regulation of the human immunodeficiency virus type 1 promoter. *J Virol*. 1996 Apr 1;70(4):2260–8.
95. Ruden M, Puri N. Novel anticancer therapeutics targeting telomerase. *Cancer Treat. Rev.* [Internet]. Elsevier Ltd; 2013 Aug 1;39(5):444–56.
96. Hochreiter AE, Xiao H, Goldblatt EM, Gryaznov SM, Miller KD, Badve S, et al. Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer. *Clin Cancer Res*. 2006 May 15;12(10):3184–92.
97. Goldblatt EM, Gentry ER, Fox MJ, Gryaznov SM, Shen C, Herbert B-S. The telomerase template antagonist GRN163L alters MDA-MB-231 breast cancer cell morphology, inhibits growth, and augments the effects of paclitaxel. *Mol Cancer Ther*. 2009 Jul 1;8(7):2027–35.
98. Hashizume R, Ozawa T, Gryaznov SM, Bollen AW, Lamborn KR, Frey WH, et al. New therapeutic approach for brain tumors: Intranasal delivery of telomerase inhibitor GRN163. *Neuro-Oncology*. 2008 Apr 1;10(2):112–20.
99. Marian CO, Cho SK, McEllin BM, Maher EA, Hatanpaa KJ, Madden CJ, et al. The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth. *Clin Cancer Res*. 2010 Jan 1;16(1):154–63.
100. Joseph I, Tressler R, Bassett E, Harley C, Buseman CM, Pattamatta P, et al. The telomerase inhibitor imetelstat depletes cancer stem cells in breast and pancreatic cancer cell lines. *Cancer Res*. 2010 Nov 15;70(22):9494–504.
101. Djojotubroto MW, Chin AC, Go N, Schaetzlein S, Manns MP, Gryaznov S, et al. Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma. *Hepatology*. 2005 Nov 1;42(5):1127–36.
102. Kozloff M, Sledge GW, Benedetti FM, Starr A. Phase I study of imetelstat (GRN163L) in combination with paclitaxel (P) and bevacizumab (B) in patients (pts) with locally recurrent or metastatic breast cancer (MBC). *J Clin Oncol*. 2010.
103. Chiappori AA, Kolevska T, Spigel DR, Hager S, Rarick M, Gadgeel S, et al. A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer. *Annals of Oncology*. 2015 Jan 23;26(2):354–62.
104. Salloum R, Hummel T, Kumar SS, Dorris K, Li S, Lin T, et al. TR-11. A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system (CNS) malignancies: a pediatric brain tumor consortium study. *Neuro-Oncology*. 2015 Apr 23;17(suppl 3):iii39–9.

105. Tefferi A, Lasho TL, Begna KH, Patnaik MM, Zblewski DL, Finke CM, et al. A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis. *N Engl J Med*. 2015 Sep 3;373(10):908–19.
106. Miao Y, Wang R, Ju H, Ren G, Guo W, Lyu J. TERT promoter mutation is absent in oral mucosal melanoma. *Oral Oncol*. 2015 Aug;51(8):e65–6.
107. Koelsche C, Sahm F, Capper D, Reuss D, Sturm D, Jones DTW, et al. Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. *Acta Neuropathol*. 2013 Dec 24;126(6):907–15.
108. Vail E, Zheng X, Zhou M, Yang X, Fallon JT, Epstein JI, et al. Telomerase reverse transcriptase promoter mutations in glandular lesions of the urinary bladder. *Ann Diagn Pathol*. 2015 Oct;19(5):301–5.
109. Huang D-S, Wang Z, He X-J, Diplas BH, Yang R, Killela PJ, et al. Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation. *Eur. J. Cancer*. 2015 May;51(8):969–76.
110. Koelsche C, Renner M, Hartmann W, Brandt R, Lehner B, Waldburger N, et al. TERT promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities. *J. Exp. Clin. Cancer Res*. 2014;33:33.
111. Wu R-C, Ayhan A, Maeda D, Kim K-R, Clarke BA, Shaw P, et al. Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy. *J Pathol*. 2014 Mar 1;232(4):473–81.
112. Papathomas TG, Oudijk L, Zwarthoff EC, Post E, Duijkers FA, van Noesel MM, et al. Telomerase reverse transcriptase promoter mutations in tumors originating from the adrenal gland and extra-adrenal paraganglia. *Endocr Relat Cancer*. 2014 Aug;21(4):653–61.
113. Liu X, Bishop J, Shan Y, Pai S, Liu D, Murugan AK, et al. Highly prevalent TERT promoter mutations in aggressive thyroid cancers. *Endocr Relat Cancer*. 2013 Aug;20(4):603–10.
114. Landa I, Ganly I, Chan TA, Mitsutake N, Matsuse M, Ibrahimasic T, et al. Frequent Somatic TERT Promoter Mutations in Thyroid Cancer: Higher Prevalence in Advanced Forms of the Disease. *Journal of Clinical Endocrinology & Metabolism*. 2013 Jul 5;:1–5.
115. Nonoguchi N, Ohta T, Oh J-E, Kim Y-H, Kleihues P, Ohgaki H. TERT promoter mutations in primary and secondary glioblastomas. *Acta Neuropathol*. 2013 Dec 17;126(6):931–7.
116. Griewank KG, Murali R, Schilling B, Scholz S, Sucker A, Song M, et al. TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours. *Br J Cancer*. 2013 Jul 23;109(2):497–501.
117. Liu X, Wu G, Shan Y, Hartmann C, Deimling von A, Xing M. Highly prevalent TERT

- promoter mutations in bladder cancer and glioblastoma. *Cell Cycle*. 2013 May 15;12(10):1637–8.
118. Tallet A, Nault J-C, Renier A, Hysi I, Galateau-Sallé F, Cazes A, et al. Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma. *Oncogene*. 2014 Jul 10;33(28):3748–52.
 119. Allory Y, Beukers W, Sagrera A, Flández M, Marqués M. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. *Eur. Urol*. 2014.
 120. Griewank KG, Schilling B, Murali R, Bielefeld N, Schwamborn M, Sucker A, et al. TERT promoter mutations are frequent in atypical fibroxanthomas and pleomorphic dermal sarcomas. *Mod. Pathol*. 2014 Apr;27(4):502–8.
 121. Zhao Y, Gao Y, Chen Z, Hu X, Zhou F, He J. Low frequency of TERT promoter somatic mutation in 313 sporadic esophageal squamous cell carcinomas. *Int J Cancer*. 2014 Jan 15;134(2):493–4.
 122. Xing M, Liu R, Liu X, Murugan AK, Zhu G. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. *Journal of Clinical ...* 2014.
 123. Liu X, Qu S, Liu R, Sheng C, Shi X, Zhu G, et al. TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer. *The Journal of Clinical Endocrinology & Metabolism*. 2014 Jun;99(6):E1130–6.
 124. Liu T, Brown TC, Juhlin CC, Andreasson A, Wang N, Bäckdahl M, et al. The activating TERT promoter mutation C228T is recurrent in subsets of adrenal tumors. *Endocr Relat Cancer*. 2014 Jun;21(3):427–34.
 125. Cárcano FM, Vidal DO, van Helvoort Lengert A, Neto CS, Queiroz L, Marques H, et al. Hotspot TERT promoter mutations are rare events in testicular germ cell tumors. *Tumour Biol*. 2015 Nov 3.
 126. Oh J-E, Ohta T, Nonoguchi N, Satomi K, Capper D, Pierscianek D, et al. Genetic alterations in gliosarcoma and giant cell glioblastoma. *Brain Pathol*. 2015 Oct 7.
 127. Griewank KG, Murali R, Schilling B, Schimming T, Möller I, Moll I, et al. TERT promoter mutations are frequent in cutaneous basal cell carcinoma and squamous cell carcinoma. *PLoS ONE*. 2013 Jan 1;8(11):e80354–4.
 128. Huang H-N, Chiang Y-C, Cheng W-F, Chen C-A, Lin M-C, Kuo K-T. Molecular alterations in endometrial and ovarian clear cell carcinomas: clinical impacts of telomerase reverse transcriptase promoter mutation. *Mod. Pathol*. 2015 Feb;28(2):303–11.
 129. Chen Y-L, Jeng Y-M, Chang C-N, Lee H-J, Hsu H-C, Lai P-L, et al. TERT promoter mutation in resectable hepatocellular carcinomas: A strong association with hepatitis C infection and absence of hepatitis B infection. *International Journal of Surgery*. Elsevier

Ltd; 2014;12(7):659–65.

130. Cevik D, Yildiz G, Ozturk M. Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations. *World J. Gastroenterol.* 2015 Jan 7;21(1):311–7.
131. Dono M, Angelini G, Cecconi M, Amaro A, Esposito AI, Mirisola V, et al. Mutation frequencies of GNAQ, GNA11, BAP1, SF3B1, EIF1AX and TERT in uveal melanoma: detection of an activating mutation in the TERT gene promoter in a single case of uveal melanoma. *Br J Cancer.* 2014 Feb 18;110(4):1058–65.
132. Liao J-Y, Tsai J-H, Jeng Y-M, Chu C-Y, Kuo K-T, Liang C-W. TERT promoter mutation is uncommon in acral lentiginous melanoma. *J. Cutan. Pathol.* 2014 Jun;41(6):504–8.
133. Lee S, Barnhill RL, Dummer R, Dalton J, Wu J, Pappo A, et al. TERT Promoter Mutations Are Predictive of Aggressive Clinical Behavior in Patients with Spitzoid Melanocytic Neoplasms. *Sci. Rep.* 2015;5:11200.
134. Jangard M, Zebary A, Ragnarsson-Olding B, Hansson J. TERT promoter mutations in sinonasal malignant melanoma: a study of 49 cases. *Melanoma Res.* 2015 Jun;25(3):185–8.
135. Macerola E, Loggini B, Giannini R, Garavello G, Giordano M, Proietti A, et al. Coexistence of TERT promoter and BRAF mutations in cutaneous melanoma is associated with more clinicopathological features of aggressiveness. *Virchows Arch.* 2015 Aug;467(2):177–84.
136. Koopmans AE, Ober K, Dubbink HJ, Paridaens D, Naus NC, Belunek S, et al. Prevalence and implications of TERT promoter mutation in uveal and conjunctival melanoma and in benign and premalignant conjunctival melanocytic lesions. *Invest. Ophthalmol. Vis. Sci.* 2014 Sep;55(9):6024–30.
137. Chindris A-M, Casler JD, Bernet VJ, Rivera M, Thomas C, Kachergus JM, et al. Clinical and molecular features of Hürthle cell carcinoma of the thyroid. *Journal of Clinical Endocrinology & Metabolism.* 2015 Jan 1;100(1):55–62.
138. Shi X, Liu R, Qu S, Zhu G, Bishop J, Liu X, et al. Association of TERT promoter mutation 1,295,228 C>T with BRAF V600E mutation, older patient age, and distant metastasis in anaplastic thyroid cancer. *The Journal of Clinical Endocrinology & Metabolism.* 2015 Apr;100(4):E632–7.
139. Muzza M, Colombo C, Rossi S, Tosi D, Cirello V, Perrino M, et al. Telomerase in differentiated thyroid cancer: promoter mutations, expression and localization. *Mol Cell Endocrinol.* 2015 Jan 5;399:288–95.
140. Fredriksson NJ, Ny L, Nilsson JA, Larsson E. Systematic analysis of noncoding somatic mutations and gene expression alterations across 14 tumor types. *Nat Genet. Nature Publishing Group;* 2014 Nov 10;46(12):1258–63.
141. Liu R, Xing M. Diagnostic and prognostic TERT promoter mutations in thyroid fine-needle aspiration biopsy. *Endocr Relat Cancer.* 2014 Oct;21(5):825–30.

142. Qasem E, Murugan AK, Al-Hindi H, Xing M, Almohanna M, Alswailem M, et al. TERT promoter mutations in thyroid cancer: a report from a Middle Eastern population. *Endocr Relat Cancer*. 2015 Dec;22(6):901–8.
143. Dettmer MS, Schmitt A, Steinert H, Capper D, Moch H, Komminoth P, et al. Tall cell papillary thyroid carcinoma: new diagnostic criteria and mutations in BRAF and TERT. *Endocr Relat Cancer*. 2015 Jun;22(3):419–29.




Figure 1




Figure 2




Figure 3




Figure 4

Molecular Cancer Research

Understanding TERT Promoter Mutations: a Common Path to Immortality

Robert J. A. Bell, H. Tomas Rube, Ana Xavier-Magalhães, et al.

Mol Cancer Res Published OnlineFirst March 3, 2016.

Updated version	Access the most recent version of this article at: doi: 10.1158/1541-7786.MCR-16-0003
Author Manuscript	Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts	Sign up to receive free email-alerts related to this article or journal.
Reprints and Subscriptions	To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org .
Permissions	To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org .